Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia  by Allon, Michael et al.
Kidney International, Vol. 34 (1988), pp. 500—506
CLINICAL INVESTIGATION
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Effects of nonsteroidal antlinflammatory drugs on renal function in
sickle cell anemia. Renal hemodynamics and solute and water handling
were evaluated in 19 sickle cell patients and 8 matched normal subjects
during water diuresis, before and after acute oral administration of a
nonsteroidal antiinflammatory drug (NSAID). Baseline GFR and RPF
were higher in the patients compared to the normals. In contrast to
normals, indomethacin and sulindac induced a 16% and 14% decrease in
GFR, respectively. Indomethacin resulted in a slight increase in Uosm
in normals, but a substantially greater rise in the patients. Following
indomethacin a greater fall in FENa, fractional solute delivery to the
diluting segment of the nephron [(CH20 + CNa±K)/GFRJ, fractional
solute reabsorption in the diluting segment [CR20/GFRI and the fraction
of distally delivered solute reabsorbed [CH2O/(CH20 + CNa+K)l was
observed in the sickle cell patients than in the normal subjects. A
similar trend, but of significantly lesser magnitude than that induced by
indomethacin, was observed following sulindnc in the sickle cell pa-
tient. The data imply that the supranormal GFR observed in the sickle
cell patients was prostaglandin-mediated. The effects of NSAID's on
renal solute and water handling in the sickle cell patients are compatible
with a prostaglandin-dependent decreased salt reabsorption in the
mcdullary thick ascending limb of Henle, together with a hyperfunc-
tioning proximal tubule. The data also imply an additional indometh-
acm-sensitive antinatriuretic effect in the diluting segment in these
patients. Moreover, the results suggest that in sickle cell anemia
sulindac may not have a "renal sparing" advantage over other
NSAID's.
Sickle cell anemia is associated with abnormalities of distal
nephron function, including impairment of urine concentration
[1, 2], acidification [3—5], and potassium excretion [6, 7]. Renal
medullary ischemia is thought to occur due to the reversible
sickling of erythrocytes when they are exposed to the hyperto-
nic environment of the vasa rectae [8]. Prolonged medullary
ischemia results in infarction and thrombosis, as demonstrated
by microradioangiography, with ultimate destruction of the
papillae [91.
It has been postulated that in response to ischemia, the
medullary tissue secretes large amounts of prostaglandins [10].
The possible role that this may play in the disordered tubular
function of sickle cell anemia has not been evaluated in detail.
It has, however, been proposed that the increased prostaglan-
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din levels may contribute to the supranormal renal plasma flow
(RPF) and glomerular filtration rate (GFR) seen in young
patients with sickle cell anemia [11], as well as to the rarity of
hypertension in this population [12, 13]. In fact, de Jong et al
[14] demonstrated a reduction in renal hemodynamics in young
patients with sickle cell anemia after treatment with the non-
steroidal antiinflammatory drug (NSAID), indomethacin. How-
ever, a mechanism whereby an increase in medullary prosta-
glandin production might affect cortical function (that is, GFR)
has not yet been demonstrated.
The renal effects of NSAID's in sickle cell anemia are of
current interest for two reasons. First, if safe, they represent an
alternative to narcotic analgesics for the treatment of pain
crises. Second, since focal segmental glomerulosclerosis is seen
commonly in sickle cell patients [15], and glomerular hyperfil-
tration has been attributed a pathogenetic role in this glomeru-
lopathy [16], the high incidence of end-stage renal disease in
this population [171 may potentially be prevented by the pro-
phylactic use of NSAID's.
The goal of the present study was to examine in greater detail
the effects of indomethacin on renal hemodynamics and on
renal handling of salt and water in patients with sickle cell
anemia, In addition, comparisons were made with another
NSAID, sulindnc, because of its putative "renal-sparing" prop-
erties [18].
Methods
Nineteen subjects with sickle cell anemia, ranging in age from
18 to 32, and eight age- and sex-matched healthy volunteers
were studied as outpatients. All sickle cell patients had a serum
creatinine of 1.1 mg/dl or less, a normal blood pressure, a
normal urinalysis (with the exception of mild proteinuria by
dipstick in three subjects), were on no medications other than
folic acid, had no other active medical problems, and were free
of pain crises for at least one week prior to study. Subjects gave
informed consent for participation in the protocol approved by
the Emory University Human Investigations Committee.
Each experiment was started at 8 a.m. after an 8 to 10 hour
overnight fast and water deprivation. After obtaining baseline
blood and urine specimens, each subject received a standard
oral water load of 20 mI/kg of tap water, consumed within 30
minutes. An indwelling catheter was inserted in the left ante-
cubital vein for blood sampling, and a second catheter in the
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right arm for infusion of fluids. Following loading doses of
inulin, 50 mg/kg body weight, and paraaminohippurate (PAH),
8 mg/kg, a continuous infusion of inulin (0.46 mg/mm/kg) and
PAH (0.17 mg/mm/kg) in normal saline was maintained through-
out the experiment at a rate of 0.5 mI/mm using a constant
infusion pump.
Throughout the experiment subjects voided spontaneously
every 20 to 30 minutes, and each time replaced their urine
output with a similar volume of tap water plus 5 ml, to allow for
insensible losses. An equilibration period of 90 to 120 minutes
allowed time to achieve steady-state plasma concentrations of
inulin and PAH, and steady-state urine flow rates. This was
followed by a control period, consisting of three consecutive,
twenty minute collections of urine with midpoint blood sam-
pling. At the end of the control period, the subjects received
one of two NSAID's as follows: sixteen sickle cell patients
received indomethacin (75 mg) orally, as did the eight normal
subjects. Six sickle cell patients, three of whom had previously
participated in the indomethacin study, received sulindac (200
mg) orally. Following administration of the drug, there was a
four-hour experimental period, during which timed urine sam-
ples were collected every 30 minutes, and blood was sampled
hourly.
Subjects remained fasting throughout the experiment, re-
frained from smoking, and were supine except when voiding.
All urine samples were placed on ice after collection. Blood was
collected in heparinized tubes, centrifuged, and the plasma
stored on ice.
At the end of each experiment, all plasma and urine speci-
mens were immediately measured for osmolality by freezing
point depression. They were then assayed for inulin, PAH,
creatinine, sodium, potassium, and in some instances, chloride.
Inulin was measured by the diphenylamine method [19), PAH
by the ethylenediamine method [20], creatinine by the alkaline
picrate method [21], sodium and potassium by flame photome-
try, and chloride by the mercuric thiocyanate method (urine) or
by ion-specific electrode (plasma). All specimens were then
stored at —70°C. Plasma specimens from the control period and
the end of experimental period were subsequently assayed for
vasopressin by radioimmunoassay (RIA) [221. The sensitivity of
this method is 2.5 pglml, with an intra-as say variability of 11.2%
at plasma concentrations in the lower range. Cross-reactivity
with oxytocin and vasotocin are both less than 0.15%. Urine
samples obtained during the control period and at the end of the
experimental period from indomethacin-treated female subjects
were assayed for prostaglandins (PG) E2 and F2 by RIA [231,
and for 6-keto-PGF1c, [241, the stable metabotite of prosta-
cycline, by RIA. All prostaglandin assays were run in duplicate.
The sensitivity of the assays for PGE2, PGF2,, and 6-keto-
PGF were 50 pg/mI, 50 pg/ml, and 20 pg/mI, respectively. The
intra-assay variability was 8.3%, 7.8%, and 9.2%, and the
inter-assay variability was 11.4%, 10.2%, and 11.5%, respec-
tively. Cross-reactivity with other prostaglandins was less than
2% for all three assays.
GFR and RPF were calculated from the inulin and PAH
clearances, respectively, using standard formulae, assuming a
renal PAH extraction ratio of 0.85 for both sickle cell patients
and normal subjects [25], and were expressed per 1.73 m2
surface area. The filtration fraction (FF) was calculated from
the ratio of GFR and RPF, and expressed as a percentage.
CNA+K represented clearance of sodium plus potassium, and
Ccr the creatinine clearance. Osmolar clearance (Cosm) was
calculated from V (Usm/Posm), where V urine flow rate
(mi/mm), UOsm = urine osmolality (mOsm/kg), and POsm =
plasma osmolality (mOsm/kg). Free water clearance (CH2O) was
calculated from V— COsm. Under conditions of water loading
CH2O reflects solute reabsorption from the water-impermeable
diluting segment of the nephron [26]. The expression [CH20 +
CNa+K]/100 ml GFR was used as a measure of fractional
delivery of filtered solute to the diluting segment of the neph-
ron, and CH20/[CH20 + CNa+Kl was used as a measure of the
fraction of distally delivered solute reabsorbed in the diluting
segment [26]. In a random sample Cc1 was substituted for
CNa+K (Results).
Baseline values represent the mean of the three control
clearance periods. Experimental values were calculated from
the mean of the last three clearance periods of the experimental
phase. (In several initial studies the experimental value was
alternatively calculated by averaging the three clearance peri-
ods encompassing the maximal decline in urine flow, in an
attempt to control for the variability in the time course of the
drug effect. This alternate method of calculations yielded re-
markably similar results [data not presented]).
Paired and unpaired Student's (-tests were used to compare
results within and between groups, respectively. The Wilcoxon
signed ranks test was used for statistical analysis of parameters
whose values did not approximate a normal distribution. A P
value < 0.05 was taken to be statistically significant.
Results
The baseline GFR and RPF were significantly higher in sickle
cell patients when compared to the normal subjects (Table 1).
The FF, however, was significantly lower in the patients,
reflecting a disproportionate increase in RPF relative to the
increase in GFR. In normal subjects, indomethacin had no
effect on GFR, RPF, or FE (Table 1). In contrast, indomethacin
resulted in a small (16%), but significant, fall in GFR in sickle
cell patients. Indomethacin produced a 10% drop in RPF in
sickle cell patients, that did not achieve statistical significance.
Neither was the FE significantly altered by the drug. A similar
mean fall in GFR (14%) was observed in the sickle cell patients
after sulindac to that seen with indomethacin (Table 1). Among
the three patients studied after both drugs, the fall in GFR
following sulindac was 16%, 16%, and 19%, as compared to
19%, 16%, and 31%, respectively, following indomethacin.
Urine osmolality after an overnight fast was lower in the
sickle cell patients (414 10 mOsm/kg) than in the normals (911
39 mOsm/kg, P < 0.001; Fig. 1). Following a water load,
urine osmolalities fell substantially in all groups (Table 2). The
values achieved, however, were significantly lower in the sickle
cell patients. In normal subjects, urine osmolality rose slightly
but significantly (10%) following indomethacin, despite contin-
ued water loading. A more dramatic (200%) rise was seen in the
sickle cell patients after indomethacin. The changes in urine
osmolality following indomethacin in the sickle cell patients did
not correlate with changes in GFR (Fig. 2A). A significant
inverse correlation was observed, however, with the change in
urine volume (Fig. 2B).
Urine volume during water diuresis was significantly higher
in the sickle cell patients than in the normal subjects (15.6 0.9
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Table 1. Changes in renal hemodynamics in normal subjects and sickle cell patients given indomethacin, and in sickle cell patients given
sulindac during water diuresis
I
Normals
indomethacin
P
I vs. II
II
Sickle cell
indomethacin
P
II vs. III
III
Sickle cell
sulindac
N 8 16 6
Age years 23.8 1.3 NS 24.1 1.0 NS 23.8 2.5
GER Baseline
DrugP
97 5
99±5
NS
<0.02
NS
119 5
100±6
<0.01
NS
NS
110 10
95±9
<0.005
RPF Baseline
DrugP
556 22
540 21
NS
<0.001
<0.001
963 71
879 55
NS
NS
NS
866 89
872 107
NS
FF Baseline
Drug
P
17.5 0.9
18.2 0.4
NS
<0.001
<0.001
12.9 0.7
11.6 0.9
NS
NS
NS
13.2 0.7
II.! 0.9
<0.02
Values represent means SE.
E
E
ci,0
Fasting Water- ND
loaded
Fig. 1. Urine osmolality after an overnight fast, after water loading,
and after indomethacin (IND) administration to water-loaded normal
subjects (D) and sickle ce//patients (•). Values represent means SE.
*Significantly different from the normal subjects; tsignificantly different
from the water-loaded value in the same group.
vs. 12.4 1.0 mI/mm, P < 0.05). When corrected for GFR,
however, urine flow rate was the same in both groups (Table 2).
Urine flow rate fell in both groups following indomethacin. The
magnitude of the fall was significantly greater in the sickle cell
patients, however, compared to that seen in normal subjects (A,
8.0 0.8 vs. 2.6 0.8 ml/minIlOO ml GFR, P < 0.001).
The baseline fractional excretion of sodium (FENa) was the
same in the sickle cell patients as in the normal subjects (Table
2). There was a small but significant fall in FENa in the normal
subjects following indomethacin. The magnitude of the fall in
the sickle cell patients was again greater than that seen in
normal subjects (A, 0.42 0.08 vs. 0.16 0.06%, P C 0.05).
Urinary potassium excretion rate was similar in both groups
under baseline conditions (68 6 ILM!min in sickle cell patients
vs. 69 7 tM/min in normals, NS). A fall in urinary potassium
excretion after indomethacin (33% in normals and 40% in sickle
cell patients) was significant (P C 0.05), but was not different
between the two groups.
Fractional free water clearance (CH2W100 ml GFR) was the
same in the patients and in the normal subjects under baseline
conditions (Table 2, Fig. 3). Indomethacin produced a 25%
decrease in fractional free water clearance in normal subjects
and a substantially greater (69%) fall in the sickle cell patients
(P C 0.001). The baseline fractional delivery of solute to the
diluting segment of the nephron, [C20 + CNa+ K]"OO ml GFR,
did not differ between the sickle cell patients and the normal
subjects (Table 2, Fig. 3). The decrease in this parameter after
indomethacin was, however, greater in the sickle cell patients
than in the normals (A, 8.2 0.9 vs. 3.0 0.7mllmin!l00 ml
GFR, P c 0.001). In a subset of four subjects (two normals and
two sickle cell patients), substitution of Cl for (Na+K) in the
preceding formula gave similar results (Baseline: 13.3 2.0 vs.
14.0 2.0, NS; after indomethacin: 8.7 2.5 vs. 9.2 2.5
ml!min!l00 ml GFR, NS).
The fractional reabsorption of distally delivered solute, CH20!
CH2O + CNa+K], remained unchanged in the normal subjects
following indomethacin. This implies that the decrease in CH20
(that is, solute reabsorption in the diluting segment) following
indomethacin is secondary to decreased delivery to this
nephron segment. Whereas baseline [CH20!CH20 + CNa+K)] in
the sickle cell patients was identical to that in the normal
subjects, there was, on the other hand, a significant fall in this
parameter after indomethacin in the patients (Table 2, Fig. 3).
In four of the sickle cell patients, C2o![C2o + CNi,+K] did not
change after indomethacin. These four did not differ from the
others in terms of the indomethacin-induced fall in GFR, but
had a relatively smaller decrease in urine flow rate, and no
change in urine osmolality. If this subgroup was excluded from
the analysis, the mean decrease in CH2W[CH2O + CNa+K] follow-
ing indomethacin exceeded thirty percent.
The effects of sulindac on the renal handling of solute and
water in sickle cell patients are summarized in Table 2. In
contrast to indomethacin, sulindac did not affect urine osmolal-
ity. Urine flow fell significantly after sullndac; the magnitude of
the fall (A, 3.5 1.0 vs. 8.0 2.8 ml!min!lOO ml GFR, P C
0.005) was less than that observed with indomethacin. Sulindac
induced a similar fall in FENa in sickle cell patients to that
observed following indomethacin. Both the fractional free wa-
ter clearance and the fractional delivery of solute to the diluting
segment were decreased significantly following sulindac, but
the extent in each instance was again less than that observed
with indomethacin (A, 3.1 1.0 vs. 7.4 0.7 mlIminIlOO ml
GFR, P C 0.005 and A, 3.5 1.1 vs. 8.2 0.9 ml!min!lOO ml
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Table 2. Changes in renal solute and water handling in normal subjects and sickle cell patients given indomet
given sulindac during water diuresis
hacin, and in sickle cell patients
I II III
Normals P Sickle cell P Sickle cell
indomethacin I vs. IL indomethacin II vs. LII sulindac
N 8 16 6
Uosm mOsm/kg Baseline
Drug
P
65 5 <0.01
72 5 0.06
<0.02
45 4
134 24
<0.01
NS
<0.05
41 3
42 2
NS
V/100 ml GFR mi/rn/n Baseline
DrugP
13.0 1.2 NS
10.2 1.1 <0.005
<0.005
13.0 1.0
5.3 0.9
<0.001
NS
<0.01
14.1 2.0
10.5 1.8
<0.02
FENa % Baseline
DrugP
1.13 0.15 NS
0.97 0.16 <0.05
<0.05
0.97 0.08
0.46 0.08
<0,001
NS
NS
1.03 0.17
0.57 0.08
<0.01
CH,o/l00 ml GFR % Baseline
DrugP
10.0 1.0 NS
7.5 1.0 <0.01
<0.002
10.8 1.0
3.6 0.9
<0.001
NS
<0.005
12.1 1.8
8.9 1.6
<0.005
[CH,o+CNa+K]/lOOmI/GFR% Baseline 11.8 1.1 NS 12.6 0.8 NS 13.4 2.0
DrugP
8.8 1.1 <0.01
<0.005
4.6 0.9
<0.005
<0.01 8.2 1.3
<0.05
CH,o/[CH,o+CN8+K]% Baseline 85 2 NS 86 1 NS 90 0.3
Drug
P
85 1 <0.05
NS
69 6
<0.005
<0.05 90 0.8
NS
Abbreviations are: urine osmolality; V, urine volume; FENa, fractional excretion of sodium; CH,o/l00 ml GFR, reabsorption of solute in
the diluting segment; [CH,O + CNa+K]/lOO ml GFR, delivery of solute to the diluting segment; CH,o/ICH,o + CNa+KI, fractional reabsorption of
distally delivered solute.
Values represent means SE.
GFR, P < 0.01, respectively). Since these two parameters
changed in an approximately proportionate fashion, the frac-
tional reabsorption of distally delivered solute, [CH,o/(CH,O +
CNa+K)], remained unchanged after sulindac (Table 2, Fig. 3).
The creatinine clearance (Ccr) in the normal subjects under
baseline conditions was 114 5 ml/min, 17% higher than the
corresponding inulin clearance, a difference that did not achieve
statistical significance. The Cr in the sickle cell patients under
baseline conditions was 154 7 ml/min, or 29% higher than the
corresponding inulin clearance (P < 0.001). The overestimation
of GFR by the creatinine clearance was greater (P < 0.05) in the
patient group than in the normals.
Plasma vasopressin levels were appropriately suppressed
during baseline water-loading in both normals and sickle cell
patients, with mean values approximately the sensitivity of the
assay. There was no increase in these values following indo-
methacin in either group. Baseline rates of urinary prostaglan-
din excretion were similar in the ten female sickle cell patients
and in the five normal females (PGE2: 1821 221 vs. 2288 267
pg/mm, NS; PGF2: 1874 275 vs. 2199 357 pg/mm, NS; and
6-keto-PGF1: 431 26 vs. 450 39 pg/mm, respectively).
Following indomethacin PGE2 excretion fell similarly by 45%
(P < 0.05) and 67% (P < 0.05), and PGF2a excretion fell
similarly by 35% (P < 0.05), and 55% (P < 0.05) in the normals
and sickle cell patients, respectively. Whereas a nonsignificant
15% decrease in 6-keto-PGF1, excretion occurred after indo-
methacin in normals, a 46% decrease (P < 0.02) was observed
in the patients.
Discussion
No change in renal hemodynamics was observed following
indomethacin in healthy euvolemic control subjects, as has
been previously reported [27, 281. In contrast, a significant
(16%) decrease in GFR was observed in patients with sickle cell
anemia, who were judged to be euvolemic based on unrestricted
diets similar to those of normal subjects, similar baseline FENa,
and supranormal baseline GFR's. These findings imply that
prostaglandins contribute to the maintenance of the GFR values
observed.
The inability of the sickle cell patients to maximally concen-
trate their urine (Fig. 1) is well known [1—3, 71. Of equal
interest, however, is their observed capacity to maximally
dilute the urine. Indeed, urine osmolalities on water loading
reached significantly lower values in the sickle cell patients than
in normal subjects, as is also apparent in a previous study [38].
Following indomethacin, normal subjects had a statistically
significant, but clinically trivial, rise in urine osmolality. Sickle
cell patients, in contrast, had a substantial increase in urine
osmolality after the drug (Fig. 1). The reason for the rise in
urine osmolality is not readily apparent, but obviously reflects
the net result of prostaglandin inhibition on solute and water
handling in the various segments of the tubule.
Since urine is isosmotic to plasma at the start of the diluting
segment, the increase in urine osmolality seen in the sickle cell
patients following indomethacin can only be explained by one
of two changes in the handling of salt and water in this segment.
The first explanation is an increase in solute-free water reab-
sorption in the collecting duct. In normal subjects, under
conditions of water loading, vasopressin is completely sup-
pressed. The observation that under baseline conditions urine
osmolalities were, if anything, lower in the sickle cell patients
than in normal subjects, suggests that vasopressin is also
completely suppressed in the patient group during water load-
ing. If the diluting segment in fact remains impermeable to
water following indomethacin, a rise in urine osmolality must be
attributed to the second explanation: a decrease in solute
504 Allon et a!: NSAID in sickle cell anemia
A
r = 0.14 P = 0.65
.
••
V
S
A
6
. 50
E
3
E 2
0D 1
0—
0.4 0.6 0.8 1.0 1.2
GFR Indomethacin
baseline
B6 r = 0.82 P< 0.001 y 5.12 — 7.90x
. 5
C'_
Urine flow lndomethacirtbaseline
Fig. 2. A. Correlation between change in glomerular filtration rate,
(indomethacin/baseline) and change in urine osmolality (indomethacini
baseline) in sickle cell patients. B. Correlation between change in urine
volume (indomethacin/baseline) and change in urine osmolality
(indomethacin/baseline) in sickle cell patients.
reabsorption in that segment. Following the administration of
indomethacin to sickle cell patients, the fractional reabsorption
of distally delivered solute, [CH2O/CH2O + CNa+K)1, decreased
from 86 to 69%. Expressed differently, the fraction of solute
delivered to the diluting segment that remained in the final urine
increased from 14% to 31%, a significant 120% increase. In the
absence of water reabsorption, this change would be expected
to result in a 120% increase in urine osmolality, from 45 to 99
mOsmlkg, which is not too different from the change actually
measured.
This decline in the fractional reabsorption of distally deliv-
ered solute in the sickle cell patients is surprising, since
prostaglandins have been shown to be natriuretic in the cortical
collecting duct 1291, and their blockade would be expected to
produce an antinatriuresis. It raises the possibility of an inde-
pendent natriuretic effect of indomethacin in the diluting seg-
ment in sickle cell patients, that may be attributable to the
formation of a natriuretic metabolite of arachidonic acid, fol-
lowing cyclooxygenase inhibition.
In spite of the apparent segmental decrease in sodium reab-
sorption in the sickle cell patients referred to above, the overall
effect of prostaglandin inhibition was antinatriuretic. A pro-
nounced fall in FENa (42%) was observed in the sickle cell
+
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Fig. 3. Changes in (A) delivery of solute to the diluting segment [CH20
+ CNO+KJ/IOO mlGFR, (B) solute reabsorption in the diluting segment,
CH20/IOO ml GFR, and (C)fractional reabsorption of distally delivered
solute, Cg2o/[CH2 + CNa+Id, in normal subjects and in sickle cell
patients, after administration of indomethacin. Values represent means
SE. Symbols are: (El) baseline; () indomethacin; *significantly
different from baseline values; tsignificantly different from the value
after indomethacin in normal subjects.
patients following indomethacin, in agreement with the findings
of de Jong et al [301. The magnitude of the drop in FENa was
substantially greater in the patient population than in the normal
subjects. This enhanced reabsorption of salt in the sickle cell
patients as compared to the normal subjects must reflect
enhanced reabsorption prior to the diluting segment.
Although the baseline fractional salt delivery to the diluting
segment, (CH2O + CNa+K)/IOO mIIGFR, was the same in the
patients as in normals, the magnitude of the fall in this param-
eter following indomethacin was greater in sickle cell patients
(63%) than in normal subjects (25%). The decrease in this
parameter following indomethacin is most likely occurring at
the medullary thick ascending limb, since prostaglandins are
natriuretic at this site [311. Such an enhanced natriuretic effect
of the prostaglandins in the medullary thick ascending limb of
Henle in sickle cell patients is not surprising, given the exist-
ence of medullary ischemia in these patients and the docu-
mented stimulation of prostaglandin production during medul-
Normals Sickle-Cell
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lary ischemia [10]. Furthermore, inhibition of this effect would
result in increased salt reabsorption from the medullary thick
ascending limb, leading to an increase in medullary interstitial
hypertonicity [32], and consequently an increase in water
abstraction from the relatively solute-impermeable descending
limb. This, in turn, would explain the decreased urine flow
during water diuresis following indomethacin in the normal
subjects, as well as the even more striking decrease observed
under these conditions in the sickle cell patients.
The enhanced natriuretic effect of prostaglandins in the
ascending limb of Henle in sickle cell patients in the face of
normal salt delivery to the diluting segment in these patients
under baseline conditions implies an enhanced solute reabsorp-
tion by the proximal tubule. Increased salt reabsorption in the
proximal tubule would be compatible with previously reported
features suggesting a "hyperfunctioning" proximal tubule in
sickle cell anemia, including increased secretion of urate [33],
and increased reabsorption of phosphate [34] and f32-microglob-
ulins [35]. The striking overestimate (29%) of GFR by the
creatinine clearance in the sickle cell patients in this study and
in a previous report [14] is also compatible with this explana-
tion, and is attributable to the enhanced creatinine secretion by
the proximal tubule. The associated decrease in solute delivery
to the ascending loop of Henle may also account for the
attenuated natriuretic effect of furosemide in these patients [6].
Although increased urinary excretion of PGE2 and PGF2a
reflects increased renal production of these prostaglandins [18],
it appears that increased intrarenal prostaglandin production
need not necessarily be reflected in increased urinary excretion.
Thus, for example, enhanced sensitivity to cyclooxygenase
inhibition has been reported in chronic renal failure patients, in
the absence of hyperprostaglandinuria [36]. Previous reports of
prostaglandin excretion in sickle cell patients [37] are difficult to
interpret due to the inclusion of males, in whom interpretation
is unreliable due to contamination from extrarenal sources [38].
In the present study, during water diuresis, baseline prostaglan-
din excretion in females with sickle cell anemia did not differ
from age- and sex- matched controls. The calculated values of
baseline urinary PGE2 and PGF2,. excretion in the controls were
higher than the previously reported normal 24-hour excretion
rates [39], attributable to the flow dependency of prostaglandin
excretion [40]. These two prostaglandins fell significantly in the
normals following indomethacin, as has been previously re-
ported [39]; a similar magnitude of change was seen in the sickle
cell patients in the present study. The nonsignificant change in
6-keto-PGF1c. excretion following indomethacin in the normals
is also in general accord with previously published data [39]. By
contrast, the prostacycline metabolite was significantly lower in
sickle cell patients than in normals following indomethacin.
Recent studies have suggested that the NSAID sulindac may
have "renal-sparing" properties, probably due to the inactiva-
tion of its active sulfide metabolite by the kidney [15]. In
contrast to normal subjects, in patients with chronic renal
failure or cirrhosis, sulindac decreases urinary prostaglandin
excretion [41, 42]. Furthermore, sulindac may produce a fall in
GFR and decrease in natriuretic efficacy of furosemide in these
patients [42—44]. Our data suggest that in sickle cell anemia
sulindac induces decreases in GFR similar to those seen with
indomethacin, although the effects on segmental solute handling
appear to be of smaller magnitude.
When patients with sickle cell anemia have acute pain crises
they are usually treated with narcotic analgesics. Recently,
there has been interest in substituting NSAID's in order to
avoid the drug dependence seen in some patients with the use of
narcotics. The current study raises some concerns over the
possible deleterious effects of NSAID's on renal function in
sickle cell anemia. Before the widespread use of these agents
can be advocated in this patient population, further studies of
the effects of their chronic administration are warranted. Ad-
vancing renal failure, most often attributable to focal segmental
glomerulosclerosis, is a common complication of sickle cell
anemia in the middle decades of life [10, 17]. The possible role
of prostaglandin-mediated supranormal GFR in the pathogene-
sis of this glomerulopathy merits consideration, as well as
studies of the potential prophylactic role of NSAID's in this
setting.
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